Spots Global Cancer Trial Database for Neoadjuvant Therapy in Biliary Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Therapy in Biliary Adenocarcinoma
Official Title: Feasibility of Total Neoadjuvant Therapy in Resectable Biliary Adenocarcinoma
Study ID: NCT04480190
Study Description
Brief Summary: Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.
Detailed Description: This trial will evaluate whether a neoadjuvant paradigm is feasible in resectable biliary adenocarcinoma. All components of therapy are currently used standards of care, however they have not been used in the neoadjuvant setting for the management of resectable biliary cancers. The study will use Gemcitabine/cisplatin, followed by chemoradiation. This is a feasibility trial with an accrual goal of 12 patients using the primary endpoint of completion of neoadjuvant therapy and surgery as an assessment of feasibility.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Contact Details
Name: Jordan Kharofa, MD
Affiliation: University of Cincinnati
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
